127 related articles for article (PubMed ID: 2265237)
1. Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet.
Shargel L; Silverman HI; Cohen P; Brisson J; Dennis S
Biopharm Drug Dispos; 1990 Oct; 11(7):569-83. PubMed ID: 2265237
[TBL] [Abstract][Full Text] [Related]
2. Phenylpropanolamine pharmacokinetics in dogs after intravenous, oral, and oral controlled-release doses.
Hussain MA; Aungst BJ; Lam G; Shefter E
Biopharm Drug Dispos; 1987; 8(5):497-505. PubMed ID: 3663885
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of multiple dosage bioavailability between phenylpropanolamine controlled release suspension and conventional tablet in healthy volunteers].
Shen YX; Xu CD; Gao XH; Lin DC; Liu GL
Yao Xue Xue Bao; 1995; 30(2):157-60. PubMed ID: 7785434
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and bioavailability of clemastine and phenylpropanolamine in single-component and combination formulations.
Schran HF; Petryk L; Chang CT; O'Connor R; Gelbert MB
J Clin Pharmacol; 1996 Oct; 36(10):911-22. PubMed ID: 8930778
[TBL] [Abstract][Full Text] [Related]
5. Comparison of effects of two dosage regimens of phenylpropanolamine on blood pressure and plasma levels in normal subjects under steady-state conditions.
Saltzman MB; Dolan MM; Doyne N
Drug Intell Clin Pharm; 1983 Oct; 17(10):746-50. PubMed ID: 6628229
[TBL] [Abstract][Full Text] [Related]
6. Steady state pharmacokinetics and dose-proportionality of phenylpropanolamine in healthy subjects.
Scherzinger SS; Dowse R; Kanfer I
J Clin Pharmacol; 1990 Apr; 30(4):372-7. PubMed ID: 2341583
[TBL] [Abstract][Full Text] [Related]
7. In-vivo pharmacokinetic characteristics of a transdermal phenylpropanolamine (PPA) preparation.
Devane J; Mulligan S; Foynes M; Martin M
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():297-9. PubMed ID: 1820895
[TBL] [Abstract][Full Text] [Related]
8. Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects.
Graf P; Toll K; Palm J; Hallén H
Acta Otolaryngol; 1999; 119(7):837-42. PubMed ID: 10687944
[TBL] [Abstract][Full Text] [Related]
9. [Bioavailability of a controlled-release suspension of phenylpropanolamine in healthy volunteers].
Chen QC; Chen WL; Dai YQ; Ge GQ; Lin DC
Yao Xue Xue Bao; 1992; 27(4):299-302. PubMed ID: 1442046
[TBL] [Abstract][Full Text] [Related]
10. Relative bioavailability of carbinoxamine and phenylpropanolamine from a retard suspension after single dose administration in healthy subjects.
Stockis A; Lebacq E; Deroubaix X; Allemon AM; Laufen H
Arzneimittelforschung; 1992 Dec; 42(12):1478-81. PubMed ID: 1363194
[TBL] [Abstract][Full Text] [Related]
11. Polyvinyl alcohol-methyl acrylate copolymers as a sustained-release oral delivery system.
DiLuccio RC; Hussain MA; CoffinBeach D; Torosian G; Shefter E; Hurwitz AR
Pharm Res; 1989 Oct; 6(10):844-7. PubMed ID: 2608626
[TBL] [Abstract][Full Text] [Related]
12. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
Modi NB; Lindemulder B; Gupta SK
J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
[TBL] [Abstract][Full Text] [Related]
13. A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine.
Noble R
Drug Intell Clin Pharm; 1988 Apr; 22(4):296-9. PubMed ID: 3286173
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
[TBL] [Abstract][Full Text] [Related]
15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
16. Determinants of the pressor effect of phenylpropanolamine in healthy subjects.
Blackburn GL; Morgan JP; Lavin PT; Noble R; Funderburk FR; Istfan N
JAMA; 1989 Jun; 261(22):3267-72. PubMed ID: 2716162
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of a new once-daily controlled-release sarpogrelate hydrochloride compared with immediate-release formulation and the effect of food.
Kim TE; Kim JR; Jung JA; Kim MJ; Lee SY; Ko JW; Jung WT; Choi YW; Lee HJ; Kim SH; Huh W
J Clin Pharm Ther; 2014 Apr; 39(2):192-5. PubMed ID: 24325365
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
19. Combined pharmacokinetic and urodynamic study of the effects of oral administration of phenylpropanolamine in female Beagle dogs.
Noël S; Cambier C; Baert K; Gustin P; Denooz R; Massart L; Hamaide A
Vet J; 2010 May; 184(2):201-7. PubMed ID: 19282207
[TBL] [Abstract][Full Text] [Related]
20. Impact of release characteristics of sinomenine hydrochloride dosage forms on its pharmacokinetics in beagle dogs.
Sun J; Shi JM; Zhang TH; Gao K; Mao JJ; Li B; Sun YH; He ZG
World J Gastroenterol; 2005 Aug; 11(29):4547-51. PubMed ID: 16052686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
